Formulation, characterisation and stability assessment of a food derived tripeptide, Leucine-Lysine-Proline loaded chitosan nanoparticles

M.K. Danish  
Dublin Institute of Technology

Giuliana Vozza  
Dublin Institute of Technology

Hugh Byrne  
Dublin Institute of Technology, hugh.byrne@dit.ie

Jesus Frias  
Dublin Institute of Technology

Sinead Ryan  
University College Dublin, Ireland

Follow this and additional works at: https://arrow.dit.ie/biophonart

Part of the Food Biotechnology Commons, Human and Clinical Nutrition Commons, Medicinal-Pharmaceutical Chemistry Commons, and the Physics Commons

Recommended Citation

This Article is brought to you for free and open access by the DIT Biophotonics and Imaging at ARROW@DIT. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@DIT. For more information, please contact yvonne.desmond@dit.ie, arrow.admin@dit.ie, brian.widdis@dit.ie.
Formulation, characterisation and stability assessment of a food derived tripeptide, Leucine-Lysine-Proline loaded chitosan nanoparticles

Minna Khalid¹², Giuliana Vozza¹², Hugh J. Byrne², Jesus M. Frias¹, Sinéad M. Ryan³
¹School of Food Science and Environmental Health, Dublin Institute of Technology,
Marlborough Street, Dublin 1, Ireland
²FOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland
³School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland

*Corresponding author. E-mail: Jesus.Frias@dit.ie
Abstract

The chicken or fish derived tripeptide, Leucine-Lysine-Proline (LKP), inhibits the Angiotensin Converting Enzyme and may be used as an alternative treatment for pre-hypertension. However, it has low permeation across the small intestine. The formulation of LKP into a nanoparticle (NP) has the potential to address this issue. LKP-loaded NPs were produced using an ionotropic gelation technique, using chitosan (CL113). Following optimisation of unloaded NPs, a mixture amount design was constructed using variable concentration of CL113 and tripolyphosphate at a fixed LKP concentration. Resultant particle sizes ranged from 120-271 nm, zeta potential values from 29-37 mV and polydispersity values from 0.3-0.6. A ratio of 6:1 (CL113: TPP) produced the best encapsulation of approximately 65%. Accelerated studies of the loaded nanoparticles indicated stability under normal storage conditions (room temperature). Cytotoxicity assessment showed no significant loss of cell viability and in vitro release studies indicated an initial burst followed by a slower and sustained release.

Keywords: chitosan nanoparticles; food derived peptide; mixture amount design; accelerated thermal stability analysis; ACE inhibition
1. Introduction

A number of synthetic antihypertensive drugs (ACE inhibitors) are currently available on the market (e.g. captopril, lasinopril and enalapril) but all have been reported to have associated adverse side effects, such as coughing, dizziness, loss of taste and skin rashes and poor pharmacokinetics with a short half life, resulting in the requirement of frequent dosage (Bougatef et al., 2008). Therefore, natural ACE inhibitors, isolated from food sources, have attracted increasing attention in recent years, in the search to find a safer and more economical approach for the consumers (Bougatef et al., 2008). Peptides derived from food sources have been reported to have health benefits such as hypotensive activity, due to their Angiotensin Converting Enzyme (ACE) inhibitory activity (Berilyn et al., 2016; Li et al., 2016). Using DNA microarray experiments it was found that other mechanisms can also contribute to the decrease of blood pressure for bioactive tripeptides (Yamaguchi, Kawaguchi, & Yamamoto, 2009) reducing the side effects of ACE inhibition. However, exploitation of the potential nutraceutical benefits of these peptides in general is known to face a number of challenges. Insufficient gastric residence time, low permeation and/or solubility within the gut, chemical degradation within the gastrointestinal tract (GIT) due to low pH, enzymatic degradation, and the presence of other nutrients (in food), all limit the bioavailability of bioactive peptides by the oral delivery route (Braithwaite et al., 2014; Ma, 2014; Segura-Campos, Chel-Guerrero, Betancur-Ancona, & Hernandez-Escalante, 2011). A number of researchers have attempted to formulate peptides into oral delivery systems for example by the addition of absorption enhancers (Choonara et al., 2014), enzyme inhibitors (Bruno, Miller, & Lim, 2013), hydrogels (Sharpe, Daily, Horava, & Peppas, 2014), liposomes (Takahashi, Uechi, Takara, Asikin, & Wada, 2009) and nanoparticles (Yao, McClements, & Xiao, 2015).
Leucine-Lysine-Proline is a tripeptide, derived from chicken muscle, which has shown in vitro ACE inhibitory activity, having a mean inhibitory concentration (IC$_{50}$) of 0.32µM (Zhou, Du, Ji, & Feng, 2012). In addition, LKP has been shown to elicit a significant reduction of blood pressure in spontaneously hypertensive rats (SHR) when delivered intravenously, 10mg/kg$^{-1}$ producing a reduction in systolic blood pressure of 75mmHg, compared to an oral dose of 60mg/kg$^{-1}$, which resulted in a reduction of 18mmHg (Fujita, Yokoyama, Yoshikawa, Iroyukifujita, & Eiichiyokoyama, 2000). Captopril, a synthetic oral ACE inhibitor drug used for the treatment of hypertension, has been reported by Quiñones et al. (2015) to show a maximum in vivo change in SHR of 60.5 ± 2.7 mmHg, 4 hours post-administration, when 50mg/kg was given orally. Recent studies have shown that LKP is stable in the GIT but with lower permeation than the market drugs, across the intestine at its target site, the small intestine (Gleeson, Heade, Ryan, & Brayden, 2015). Formulation into nanoparticles (NPs) for oral delivery can enhance the bioavailability of an encapsulated peptide drug and consequently improve its pharmacokinetics and stability (Patel, Patel, Yang, & Mitra, 2014; Ryan et al., 2013). Stable NPs with particle sizes ranging between 100-500nm (des Rieux, Fievez, Garinot, Schneider, & Préat, 2006), zeta potential values (ZP) ≥ 30mV (Lakshmi & Kumar, 2010), polydispersity (PDI) < 0.400 (Abdel-Hafez, Hathout, & Sammour, 2014a) and maximum encapsulation efficiency are ideal characteristics for oral supplementation.

Chitosan is a linear polysaccharide, prepared by N-deacetylation of chitin (Rinaudo, 2006). Chitosan NPs have shown promising results for oral delivery/supplementation due their GRAS properties and their intrinsic properties, including, non-immunogenic, mucoadhesion and the ability to transiently open the tight junctions of the intestinal barrier, which can help facilitate transport of macromolecules and has the potential to act as an enhancer (Chuah, Kuroiwa, Ichikawa, Kobayashi, & Nakajima, 2009; de Moura et al., 2009; Madureira,
Pereira, & Pintado, 2016). LKP NPs were produced using an ionotropic gelation technique. This technique allows the preparation of chitosan NPs in aqueous solution and avoids the use of organic solvents, high dispersion energy and harsh conditions, making the technique suitable for the inclusion of nutraceuticals (García, Forbe, & Gonzalez, 2010). In this process, a chitosan with a high degree of deacetylation is used, which increases the viscosity and results in an extended conformation with a more flexible chain because of the charge repulsion in the molecule (Franca, Freitas, & Lins, 2011). Chitosan can be ionically cross-linked by counterions, such as sodium tripolyphosphate (TPP), to form a hydrogel of microparticles, and when the relative concentrations of chitosan and these anions are appropriate, NPs may be generated (Sureshkumar, Das, Mallia, & Gupta, 2010).

The formulation of NPs from different constituent components can be troublesome, due to the different variable parameters used (concentration, temperature and pH). Empirical optimisation using Response Surface Modelling (RSM) can help to rationalise the process and has found applications in different fields, such as engineering, pharmaceutical, biomedical, environmental and epidemiological research (Singh, Singh, Saraf, & Saraf, 2011). RSM has been shown to be useful for optimisation of experimental parameters in nanoparticle formulation, and has been adopted by a number of research groups (Abdel-Hafez, Hathout, & Sammour, 2014b; Bezerra, Santelli, Oliveira, Villar, & Escaleira, 2008).

The aim of this work is to formulate and investigate the feasibility of LKP encapsulated chitosan NPs, determining the physico-chemical characteristics, stability to storage, bioactivity and low cytotoxicity properties. The formulation of the LKP NP was optimised using a RSM approach. The physico-chemical characteristics of the NPs were assessed using dynamic laser scattering, scanning electron microscopy, and Fourier transform infrared spectroscopy, with the aim of producing the optimal NPs as an oral delivery system. Accelerated thermal conditions are employed to explore the stability for future storage.
conditions; particle size, polydispersity, zeta potential and bioactivity were assessed. In addition, the cytotoxicity and release profiles in simulated gastric and intestinal fluids were assessed.

2. Materials and Methods

LKP (Mw 356.47, purity = 96% according to the manufacturer’s specifications) was synthesised by ChinaPeptides Co. Ltd, (Shanghai, China). CL113 (Mw = 110 kDa, deacetylation degree (DD) = 86% according to manufacturer’s specifications) was obtained from Pronova Biopolymer (Norway). TPP, Angiotensin-I converting enzyme (from rabbit lung), captopril, N-α-hippuryl-L-histidyl-L-leucine hydrate salt (HHL) and all other materials were obtained from Sigma-Aldrich (Ireland). CellTitre 96® AQueous One Solution Cell Proliferation Assay was supplied by Promega (Madison, USA). Caco-2 cells (passage 24-26) were obtained from European Collection of Cell Cultures (Salisbury, UK). HepG2 cells (passage 32-34) were obtained from American Type Culture Collection. Ultrapure water was used for all experiments and was obtained from a Milli-Q water purification system (Millipore Corporation, USA).

2.1 Unloaded nanoparticle formulation design

Unloaded NPs formulation was optimised using varying concentrations of CL113 and TPP, following a 3 block Central Composite Design (CCD) with 2 variable parameters and 3 responses (particle size, ZP and PDI).

2.2 LKP nanoparticle formulation design

A Mixture Amount Design (MAD) was employed using the concentration ranges of chitosan (CL113) and TPP (see table 1) around the optimal point (1.5mg/mL CL113 and 0.3mg/mL TPP) suggested from preliminary unloaded particle experiments (Section 3.1). The
experimental design and data analysis was performed using Minitab 17 software (Minitab Inc, USA).

**Table 1** MAD for LKP nanoparticles at optimised CL113, TPP concentration

<table>
<thead>
<tr>
<th>Sample</th>
<th>CL113 (mg/ml)</th>
<th>TPP (mg/ml)</th>
<th>Ratio (CL113/TPP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.64</td>
<td>0.21</td>
<td>8.0</td>
</tr>
<tr>
<td>2</td>
<td>1.52</td>
<td>0.33</td>
<td>4.5</td>
</tr>
<tr>
<td>3</td>
<td>1.58</td>
<td>0.27</td>
<td>5.9</td>
</tr>
<tr>
<td>4</td>
<td>1.45</td>
<td>0.40</td>
<td>3.6</td>
</tr>
<tr>
<td>5</td>
<td>1.39</td>
<td>0.46</td>
<td>3.0</td>
</tr>
</tbody>
</table>

2.3 Preparation of LKP NPs

Preparation of LKP NPs was based on a modified ionotropic method (Calvo, Remu, Pez, Vila-Jato, & Alonso, 1997; Vimal et al., 2013). Stock solutions of 10mg/mL CL113 and TPP were prepared. CL113 was dispersed in acetate buffer (pH3) and TPP in 0.01M sodium hydroxide solution. The stock solutions of CL113 and TPP were diluted to different concentration ratios at a fixed volume mixture of 2.5:1 CL113: TPP containing solution. A fixed concentration of 0.1mg/mL LKP was added to the diluted TPP solutions. The TPP/peptide solution was added dropwise to the CL113 solution while stirring (800rpm for 30mins). NPs were separated using ultrafiltration-centrifugation (Centriplus YM-30, MWCO of 30kDa, Millipore, USA). 10mL of sample were placed in the sample reservoir of the centrifugal filter device and centrifuged for 30mins at 3000rpm. After separation, the volume of the solution in the filtrate vial was measured and the filtrate was assayed for the amount of LKP by Reverse Phase High Performance Liquid Chromatography (RP-HPLC). The wet
pellet was re-suspended in purified water and immediately characterised using a range of physico-chemical techniques.

2.4 Physico-chemical characterisation of LKP NPs

2.4.1 Size, zeta potential and polydispersity index

The nanoparticle size (number distribution) and electrophoretic mobility measurements were performed using folded capillary cells in a Nanosizer ZS fitted with a 633 nm laser (Malvern Instruments Ltd.). Each analysis was carried out at 25°C with the equilibration time set to 2 min using size by intensity distribution.

2.4.2 Fourier transform infrared spectroscopy

The chemical properties of the NPs were monitored using Fourier transform infrared spectroscopy (FT-IR), performed using a Perkin Elmer Spotlight 400 Series Spectrometer (with Universal Attenuated total reflectance (ATR) accessory). FT-IR spectra of LKP, unloaded NPs, and LKP NPs were obtained in the spectral range 650 to 4000 cm\(^{-1}\) in triplicate. NP samples were stored at -80°C in glass vials and then lyophilised prior to analysis using a Labconco FreeZone 6 Liter Benchtop Freeze Dry System.

2.4.3 Scanning electron microscopy

The morphology of the freeze-dried NPs was studied using scanning electron microscopy (SEM) (Hitachi SU6600 FESEM), at an accelerating voltage of 20kV using the secondary electron detector. The freeze dried NPs (0.5mg) were dispersed in deionised water (10mL) and sonicated for 4min. One drop of the dispersion containing LKP NPs was placed on a silicon wafer and dried at room temperature. This was sputter coated with 4nm Au/Pd prior to imaging.
The association efficiency (AE) and loading capacity (LC) of NPs was calculated by the indirect method of Al-Qadi et al. (2012). The supernatant was assayed for the content of LKP by RP-HPLC. This quantity of LKP is referred to as the non-associated peptide. The RP-HPLC analysis was performed on a Waters 1525 pump (Waters, Milford, Massachusetts) with a Photo Diode Array detector 2487 (Waters) using a Luna C18 column (5µm, 250mm x 4.6mm, Phenomenex). Analytes were detected at the wavelength of $\lambda_{\text{max}} = 220\text{nm}$. The column was eluted at a flow rate of $1\text{mL.min}^{-1}$ with an isocratic system (15% Acetonitrile, 0.05% TFA in water). The AE% and loading capacity (LC %) was calculated using the following equations.

\[
\text{AE} \% = \left( \frac{\text{Total amount Peptide} - \text{free amount Peptide in supernatant}}{\text{Total amount of Peptide}} \right) \times 100 \quad (4.1)
\]

\[
\text{LC} \% = \left( \frac{\text{Total amount Peptide} - \text{free amount Peptide in supernatant}}{\text{Nanoparticle weight}} \right) \times 100 \quad (4.2)
\]

The ACE inhibition of LKP was determined as previously described with minor modifications (Henda et al., 2013; Lahogue, Réhel, Taupin, Haras, & Allaume, 2010). All solutions were pre-filtered with 0.22µm nylon syringes prior to analysis. HHL (5mM) was dissolved in pH 8.3 buffer (0.1M borate buffer in 0.3M NaCL). In a 96-well plate, 100µl substrate solution and 25µl inhibitor were incubated for 10min at 37°C. 10µl ACE solution (100mU/mL) was then added and incubated for another 30min at 37°C. The assay was terminated using 100µl of 1M HCL. HPLC was performed using a C8 column (2.7µm, 3.0 x 100mm, Agilent Technologies UK & Ireland Ltd) and wavelength detection at $\lambda_{\text{max}} = 228\text{nm}$. An isocratic method was used at a flow rate of $0.4\text{mL.min}^{-1}$, 25% Acetonitrile, 0.1% TFA in water for 5min. Controls were prepared by replacing the inhibitor with assay buffer (negative
control) and captopril (positive control). 100% ACE inhibition (negative control) was used to calculate the % of ACE activity.

\[ ACE\ inhibition\ (%) = \left( 1 - \frac{A_{\text{inhibitor}}}{A_{\text{blank}}} \right) \times 100 \]  

(4.3)

where \( A_{\text{inhibitor}} \) and \( A_{\text{blank}} \) are the peak areas of HA (product of HHL) and negative control, respectively. The IC\textsubscript{50} of the inhibitor was determined using the Hill-Step equation (Prism 5, GrapPad Software Inc., USA).

2.4.6 Accelerated stability analysis

The optimal formulation was further analysed under accelerated stability conditions. 10mL of a NP formulation equivalent to 19.5mg of NPs were resuspended in aqueous solution (pH7) and stored at accelerated conditions; 60°C for 720min, 70°C for 300min and 80°C for 120min. The particle size and colloidal stability over different time intervals were measured using the Nanosizer ZS (Malvern Instruments Ltd), and the order of degradation in aqueous LKP suspension was determined. The end point of each sample was further assessed for ACE inhibition activity (Method 2.4.5). Stability analysis was analysed using R software (R Core Team, 2015).

The kinetic model used to describe the stability was of zero order. The temperature dependence of the kinetic parameters of LKP NPs stability was measured by calculating the observed rate constants. This was plotted according to the Arrhenius equation and apparent activation energy, \( E_a \) and reaction rate, \( k_{\text{ref}} \) were calculated according to Equation 4 (Brauner & Shacham, 1997).

\[ C = C_0 + e^{\ln(k) \cdot \frac{E_a}{R} \left( \frac{1}{t} - \frac{1}{t_{\text{ref}}} \right)} \]  

(4.4)

where \( C \) is the property (particle size or PDI) at time \( t \), \( C_0 \) is the initial property conditions, \( k \) is the apparent zero order reaction constant, \( E_a \) is the energy of activation, \( R \) is the universal
gas constant, T is the temperature of the experiment (K) and \( T_{\text{ref}} \) is the reference temperature (70°C).

2.4.7 MTS assay

Caco-2, heterogeneous human epithelial colorectal adenocarcinoma cells and HepG2, a human liver cancer cell line, were seeded at a cell density of 2 x 10^4 cells/well and cultured on 96 well plates in DMEM and EMEM respectively, supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% penicillin-streptomycin and 1% non-essential amino acids, and incubated for 24h at 37°C in a humidified incubator with 5% CO\(_2\) and 95% O\(_2\). Specified exposure times were used for Caco-2 and HepG2, in order to mimic in vivo conditions. The maximum time NPs will be exposed to the intestines are 4h, hence a 4h exposure time was used in Caco-2 cell lines (Neves, Martins, Segundo, & Reis, 2016). In addition to this, 72h exposure time was used for HepG2 cell line to mimic the liver (Brayden, Gleeson, & Walsh, 2014). LKP (native), unloaded NP and LKP NPs at 1, 5 and 10mM concentration were assessed. Triton X-100™ (0.05%) was used as a positive control. After exposure, treatments were removed and replaced with MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium. Optical density (OD) was measured at 490 nm. Each value presented was normalised against untreated control and calculated from three separate experiments, each of which included six replicates.

2.4.8 In vitro controlled release studies

LKP release from loaded formulation was carried out using a dialysis bag diffusion technique (Hosseinzadeh, Atyabi, Dinarvand, & Ostad, 2012) over 24h (Calderon et al., 2013; Yoon et al., 2014). To ensure sink conditions, NPs were solubilised and sonicated 3 times for 20 seconds (Branson Ultrasonics; Ultrasonic processor VCX-750W, Wilmington, North Carolina, USA). 5mL of LKP formulation was placed in the dialysis bag (cellulose ester...
membrane, molecular weight cut-off 100kDa, Float-A-Lyzer®G2, Sigma-Aldrich, Ireland) and immersed in a vessel containing 50mL of release fluid using simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) specified according to the British Pharmacopoeia, respectively. SGF was composed of 0.1 M HCL and SIF, as the buffering stage, was composed of 1 volume of 0.2 M trisodium phosphate dodecahydrate and 3 volumes of 0.1 M HCL (adjusted to pH 6.8), without enzymes (British Pharmacopoeia Commission, 2016). Each experiment was agitated at 100rpm, 37°C using a thermostatic shaker. At predetermined time points over 24h, 1mL of release fluid was analysed and replaced with simulated fluid. The LKP release was measured using RP-HPLC. The following equation was employed to determine the % cumulative drug release:

% cumulative release = \( \frac{LKP \text{ release}}{LKP \text{ initial}} \times 100 \)  (4.5)

where LKP release and initial represents the concentration of LKP release and the amount of LKP initially loaded into the NPs, respectively.

3. Results and discussion

LKP has an isoelectric point (pI) of 9.17, calculated using the Henderson-Hasselbach equation (Henriksson, Englund, Johansson, & Lundahl, 1995). This is the net charge of a molecule indicating that, at a pH of 9.17, LKP will have minimal solubility. At pH values below the pI, peptides carry a net positive charge and above the pI, a negative charge. LKP has a similar charge to TPP, and hence LKP was dissolved in the TPP solution. TPP-LKP was then added dropwise to the CL113 solution, resulting in the formation of opalescent NPs.

3.1 Unloaded nanoparticle production feasibility zone identification

The formulation of CL113 NPs was optimized using a CCD factorial design to analyse the effect of the pH, CL113: TPP ratio and acetic acid concentration on the size and ZP of the particles. Preliminary studies were conducted to select the most feasible region for the
formulation of peptide NPs (figure 1). This showed that > 1.25 mg/mL CLL113 and 0.25-0.3 mg/mL TPP resulted in unloaded NPs of optimal sizes of 300 nm and ZP > 30 mV.

![Overlaid contour plots of Size and ZP: the targeted area is highlighted (white).](image)

This result is in agreement with Calvo et al., (1997) who reported that concentrations which exceed 4mg/mL and 0.75mg/mL respectively for chitosan and TPP resulted in the formation of large aggregates. Nanoparticles of the desired characteristics were found to be produced at concentrations of 0.28 mg/mL (TPP) and 1.25 mg/mL (Chitosan). In addition, studies done by de Pinho Neves et al. (2014) showed similar results within the 5 to 6:1 ratio. Unloaded CL113 NPs were used as control for peptide-loaded experiments.

### 3.2 Nanoparticle size, zeta potential analysis and AE % of LKP nanoparticles

From the preliminary optimisation analysis of unloaded CL113 NPs; a CL113 concentration of 1.5mg/mL was chosen as the centre point for the MAD. LKP NP size values ranged from 120 to 271 nm, with ZP values above 30 mV. With regards to the AE % (figure 2), at ratios above 5.9, there is less variability (error bars), but at a ratio of 8, stable agglomerates (> 30 mV ZP) of variable sizes are observed.
Figure 2 Scatterplot of (a) Size (nm), (b) PDI, (c) ZP (mV) and (d) association efficiency (AE %) of LKP NPs against different ratios of (CL113/TPP). Error bars represent the individual 95% Confidence interval for the average.

An initial observation of the results at different ratios seems to indicate that the ratio of 5.9 is the best performing in terms of higher AE% and lower PDI, while still maintaining a particle size (150nm) and a ZP (>30mv) that indicates stability (figure 2). LC% for all experiments showed no significant differences, values ranged from 2-3% (see supplementary material, S2) were attained. Studies from other groups showed that an increase of counterion (TPP) concentration results in a decrease of LC due to the high level of crosslinking, causing the encapsulated material to come out of the particle (Woranuch & Yoksan, 2013).

Similar profiles are seen for the 3 responses, size (nm), ZP (mV) and PDI, suggesting agglomeration and colloidal instability above a ratio (CL113/TPP) of 7. The degree of crosslinking can be assessed by the chitosan concentration and the available NH3+ able to be crosslinked with TPP functional groups. At intermediate operation conditions, i.e. ratios between 7 and 5.5, most responses present a lower variation between replicates with respect
to all responses and a minimum PDI. Analysis for all experimental results shows particle sizes within the optimal size range (100-500nm) and ZP above 30mV values. However, for some experimental conditions, the AE% and PDI exhibited values far from the optimal physico-chemical characteristics and had high variability between replicates (N=3). At (CLL113/TPP) ratios above 7 and below 4.5, the NPs exhibited higher PDI and, below a ratio of 6, significant variability of AE% amongst replicates is evident.

The results obtained were consistent with those observed for unloaded CL113 NPs in terms of particle size, although a significant increase in colloidal stability for the loaded NPs was observed (see figure 3).
Figure 3 Boxplot for LKP NPs where each Group represents 1: control (unloaded NPs) and 2: LKP NPs. The changes of each group are examined for A: particle size, B: ZP and C: PDI. A significant increase in ZP is seen for loaded NPs with a decrease of variability. For the MAD design, a third order polynomial regression model was employed to describe the variation of size (nm), ZP (mV), PDI and AE % of the LKP NPs against the ratio (CL113/TPP). The polynomial equation parameters for each response against ratio were fitted. The models were built with the aim of identifying conditions within the experimental
design where NPs would be present as monodispersed, stable NPs with maximum peptide
encapsulation (see supplementary information S1).

From the results obtained, a ratio of 5.9 provided the most promising results, for optimal oral
delivery fulfilling the formulation constraints; 100-500 nm, PDI <0.4 and |ZP| >30 mV. In
comparison, NPs produced at a ratio of 7.8, presented the highest variability for size (206 ±
73 nm), PDI (0.4 ± 0.2), ZP (38 ± 6 mV) and AE (41 ± 11%). Notably, the NPs produced at a
ratio of 5.9 (CL113/TPP) yielded a substantially higher AE % of around 65%. It should be
noted that the LKP of isoelectric pH (9.17) was added to a higher pH TPP (pH 12) solution.
This provided more negatively charged molecules to interact with chitosan, consequently
increasing the AE % (Acton, 2012). This finding is in agreement with Silva et al.,(2013), who
observed higher AE % of daptomycin at higher pH values relative to the isoelectric pH. In
addition, LKP has a low Mw and studies of lower Mw actives showed higher AE %. This
trend was observed by Jarudilokkul et al., (2011), who showed that α-Lactalbumin (17.4 kDa)
has higher AE % than Fibrinogen (340 kDa).

3.3 Morphological characterisation of LKP chitosan nanoparticles

Further characterisation of the NPs produced with the optimal (CL113/TPP) ratio of 5.9 was
performed. Figure 4 represents an SEM image of LKP formulation, confirming the formation
of the NPs. Spheroidal NPs were obtained, of sizes ranging from 150-250nm, consistent with
the DLS measurement.
3.4 Chemical Characterisation of LKP nanoparticles

FT-IR was used to identify whether there were variations in chemical functional groups presented in the LKP loaded NPs with respect to their raw materials. An FT-IR analysis was conducted for pure LKP powder, unloaded NPs and LKP NPs (Figure 5). Chitosan NPs have been previously characterised using FT-IR (Mohammadpour Dounighi et al., 2012; Sureshkumar et al., 2010; Vimal et al., 2013).

Comparison of the FT-IR spectra of loaded and unloaded NPs indicated that the spectrum of the unloaded NPs is largely unchanged by the presence of LKP, as may be expected due to the relatively low LKP content. Characteristic peaks of unloaded NPs are seen in both, at 1530, 1636 and 880 cm\(^{-1}\), representing the amide I and amide II bands of CL113 and pyranose (P-O) of TPP. For the optimal formulation, 18.5mg of NPs is needed to encapsulate 1mg of LKP. Hence, no distinctive peaks of LKP can be seen in the LKP spectrum. The FT-IR spectrum of LKP NPs does, however, show some changes from that of the unloaded NPs, potentially indicative of localised conformational changes of the CL113 as a result of interaction with the LKP (figure 5). An increased absorption at 3386 cm\(^{-1}\) compared to that of the unloaded NPs is observed. Absorption in this region of the spectrum represents O-H bonding; a possible explanation may be due to the interaction of the hydrogen acceptors (O-
in LKP) and hydrogen donors (NH$_3^+$ in chitosan). In addition, increased absorption is also seen for LKP NPs at 2955 cm$^{-1}$, representing an increase in (C-H) hydrogen bond stretching with presence of the peptide. A shift of 1605 cm$^{-1}$ to 1530 cm$^{-1}$ was also observed which represent the amide carbonyl stretch (Mohammadpour Dounighi et al., 2012). The peaks at 1210 cm$^{-1}$ and 880 cm$^{-1}$ represent phosphate group (P-O) and pyranose ring (Woranuch & Yoksan, 2013). The peak at 1051 cm$^{-1}$ shows a split for the loaded NPs, suggesting a conformational change due to the interaction with the LKP.

![FT-IR spectra](image)

**Figure 5** FT-IR spectra of (a) LKP NPs (b) unloaded NPs and (c) Pure LKP powder. Absorbance spectra are normalised and offset for clarity.

### 3.5 IC$_{50}$ determination of inhibitor

The inhibitory activities of captopril (reference molecule) and LKP were determined using a synthetic substrate, HHL, and varying concentrations over the range 0.0001 – 10µM (captopril) and 0.001 - 10µM (LKP). The IC$_{50}$ obtained was 0.006 ± 0.002 µM for captopril and 0.30 ± 0.08 µM for LKP. These values are consistent with previously reported values,
which range from 0.001-0.039µM for Captopril and 0.2-0.32µM for LKP (Fujita & Yoshikawa 1999; Fujita et al. 2000; Henda et al. 2013).

3.6 Accelerated stability analysis of LKP NPs

In accelerated stability testing, a product is stressed at high temperatures and degradation/stability of the product at normal storage conditions is then predicted (Bajaj, Singla, & Sakhuja, 2012; Rauk, Guo, Hu, Cahya, & Weiss, 2014; Waterman & Adami, 2005). A number of factors can affect the solution stability of NPs, for example, the pH of the aqueous solvents, light, oxygen, co-solutes, buffer salts, surfactants and antioxidants. Common degradation routes include hydrolysis/solvolyis, photolysis/oxidation and racemisation (Weber, Coester, Kreuter, & Langer, 2000). A number of groups have found that CL113 NPs synthesised by ionic gelation lose their integrity in aqueous media, even in the absence of enzymes (López-León, Carvalho, Seijo, Ortega-Vinuesa, & Bastos-González, 2005). Jonassen et al. (2012) looked at the effect of different ionic strength over the course of a month; the main findings were that the most stable NPs with respect to the size and compactness of the particles were produced in saline conditions (Jonassen, Kjøniksen, & Hiorth, 2012). A similar study was also conducted, preparing NPs in different ionic strength and buffers, and results showed that the least stable NPs were produced in non-buffered solutions or low ionic solutions (López-León et al., 2005).

The stability of formulations can be tested using a number of testing protocols, which include real time stability testing, accelerated stability testing, retained sample stability testing and cyclic temperature stress testing (Bajaj et al., 2012). In the current study, accelerated stability testing was used, by which NPs are subjected to stress and then assayed simultaneously to predict the likelihood of instability based upon the Arrhenius equation. Suspensions of NPs in buffered solutions (PBS pH 7), formulated at a ratio of 5.9 CL113:TPP (optimal LKP loaded...
NPs), were exposed to three different storage temperatures, 60°C, 70°C and 80°C, over a
time course of 120, 300 and 720 min at each temperature. Figure 6 shows the kinetic
behaviour of the particle sizes at different temperatures. The stability of the NPs decreased
with increasing temperature. At 60°C, no change in particle size was observed over the
720 min. Figure 6 indicates a more pronounced increase in both particle size and PDI at 70°C,
while at 80°C, both particle size and PDI increase significantly over the time course. At this
temperature, the particle size was seen to increase monotonically from 200 to 600 nm, while
the PDI increases from 0.4 to 0.7. While some curvature is apparent in the trends at the
highest temperature, within the present experimental error, an apparent zero order mechanism
fitted better to all the data, compared to an apparent first or second order model.
Figure 6 Particle size and PDI analysis of LKP loaded NPs exposed at (a) 60°C (b) 70°C and (c) 80°C over time periods of 120, 300 and 720 min, respectively. N= 3

An Arrhenius plot of the apparent zero order reaction rate constants, derived from the analysis of the individual experiments at the different temperatures, indicates that the kinetics of the particle size and PDI followed this temperature relationship, consistent with an energy activated process, with similar energies of activation for particle size and PDI (see Figure 7).

The one-step nonlinear regression analysis of the kinetic experiments shows that the particle size fits to a zero order kinetic behaviour and an Arrhenius dependence with $\ln (k_{\text{ref}@70^\circC}) = -3 \pm 1 \text{ min}^{-1}$ and an $E_a$ of $= 360 \pm 103 \text{ kJ/mol}$. For the PDI, a one-step nonlinear regression was fitted to zero order kinetics with an Arrhenius dependence of $\ln (k_{\text{ref}@70^\circC}) = -8.9 \pm 0.3 \text{ mins}^{-1}$ and $E_a = 196 \pm 33 \text{ kJ/mol}$. A linear correlation is evident between $1/T$ and $\ln k$ in figure 7.
From this analysis, it suggests the nanoparticle formulation would be stable (in terms of particle physico-chemical properties) in a neutral pH solution at ambient storage temperature, with negligible increases in particle size or PDI of the NPs, confirming the higher stability of NPs prepared in buffered solutions. Only after 90min destabilisation of NPs was observed at the highest temperature conditions. These results are in agreement with previous literature, reporting that when NPs are produced in salt or buffered environment, stability is improved (López-León et al., 2005).

Figure 7 Arrhenius Plots for the (a) Particle Size and (b) PDI accelerated studies of LKP loaded NPs. N=3

The results suggest either (i) swelling of the chitosan NPs in the aqueous environment (Bajpai & Maan, 2012) or (ii) agglomeration of chitosan NPs due to electrostatic interactions with an increase of temperature. In order to confirm the type of degradation, the zeta potential was assessed. Destabilisation of NP suspensions which would give rise to aggregation should be reflected in changes in ZP values when NPs aggregate. However, no significant changes were seen for the colloidal stability (i.e. ZP of LKP NPs). This suggests that swelling could be the primary mechanism of the CL113 nanoparticle changes with time, followed by destabilisation at higher temperatures and longer time (see figure 8).
Figure 8 Zeta potential analyses of LKP-loaded NPs at (a) 60°C, (b) 70°C and (c) 80°C. No significant changes were observed with One-Way ANOVA with Dunnetts’s post-test. Each value represents the mean ± SD (n=3)

In addition, DD of CL113 used for this experiment is greater than 85%, it has been previously reported that with an increase of DD the aggregation stability decreases due to the CL113 more prone to TPP bridging which causes it to become more lyophobic near physiological pH which may contribute to the stability of the NPs (Huang, Cai, & Lapitsky, 2015). Overall, the accelerated experiments on LKP NPs indicate that the formulations will be stable under normal storage conditions. This could be due to the conditions (presence of salt) used to prepare the NPs, in addition to the strong bonding between the bioactive and complex.

3.7 Cytotoxicity assessment of LKP nanoparticles

The MTS assay was used to assess the cytotoxicity of LKP and LKP NPs. The therapeutic dose of LKP is 10mg/kg (Fujita et al., 2000; Fujita & Yoshikawa, 1999b). Hence, LKP loaded or unloaded NPs at the different concentrations (1, 5 and 10mM) when exposed to Caco2 (4h) and HepG2 (72h) cell lines. No cytotoxicity was observed for LKP, indicating
negligible overall cytotoxicity of the formulation (figure 9). No significant changes were observed. A number of deviations were observed above 100% viability for NPs with and without LKP, proliferation may occur due to increase in fibroblasts production caused by the presence of polymeric chitosan (Rajam, Pulavendran, Rose, & Mandal, 2011) or interference of NPs with the cell assay (Casey et al., 2007).

![Figure 9 Cytotoxicity assessment of LKP, unloaded NPs and LKP NPs exposed for (a) 4h in Caco2 cell lines and (b) 72h in HepG2 cell line at 1mM, 5mM and 10mM concentration. Percentage (%) of MTS converted was compared to untreated control. 1-Way ANOVA with Dunnetts’s post-test *** P< 0.001, ** P< 0.01, N=3](image)

3.8 In vitro release studies

The release of a bioactive can take place by several different mechanisms, for example surface erosion, disintegration, diffusion and desorption (Hosseini, Zandi, Rezaei, & Farahmandghavi, 2013). Such a phenomenon can be influenced by a number of factors such as the type of polymer used, the polymeric swelling capability, the solute diffusion and material degradation (Fu & Kao, 2009; Siepmann & Göpferich, 2001). The in vitro LKP release profiles of the NP formulation in SGF and SIF were measured over 24h, using RP-HPLC at 220nm at different time points. The site of target for LKP is in the jejunum, small
intestine, therefore it is important to bypass the acidic stomach environment. LKP NPs results showed an initial burst followed by a slow release. Similar results were reported by other groups, Hosseini et al. 2013 and Luo et al. 2010. Hosseini et al. 2013, they observed a “biphasic release” mechanism (initial burst followed by slower release) with oregano essential oil when encapsulated into CL113 NPs. Luo et al. 2010, encapsulated selenite in chitosan NPs, demonstrating the effect of CL113 concentration on the release profile. They found that, at high concentrations of chitosan, more dense particles were found which ultimately lowered the epithelial membrane permeability. Conflicting results have been reported of the release mechanism of chitosan nanoparticles. Some groups observed the inability of chitosan based nanoparticles to sustain the release of an active following an initial burst release at higher ratios of CL113 and TPP (Stoica & Ion, 2013). Others reported a controlled release; for example, Nallamuthu, Devi, & Khanum, (2015) observed the 69% release of chlorogenic acid over 100 h. Release profiles at 1.5mg/ml CL113 also showed a burst within the first 30min in the SGF followed by a slower release from 30min to 2h then a more slow sustained release up to 24h, as shown in figure 10. For LKP NPs, the initial burst may possibly represent loosely bound LKP around the CL113 NP. Within the first hour, 62% ±3 and 74% ±4 LKP was released in (a) SGF and (b) SIF, significance was observed for SGF vs SIF using a t-test, where P = 0.0074, respectively (figure 10). 12% more release was observed in the SIF (site of target) at pH 6.8. Chitosan has an isoelectric point of 6.5, at which pH chitosan holds a charge of zero (no charge), causing it to become unstable and precipitate out; consequently releasing more of the loaded peptide. It has been suggested by Gan & Wang, (2007) that a burst release of protein molecules may correspond to the fast swelling and degradation of the nanoparticles. This swelling phenomenon can be observed in (figure 10) After 1h, a slower release is observed, this may be attributed to the more strongly bound LKP loaded within the CL113 nanoparticle. A burst release has previously been
reported from other groups working with chitosan NPs, Sarmento et al. (2007) showed a similar undesirable burst of 50% insulin chitosan NPs when complexed with alginate. Ryan et al. (2013) also reported an initial burst of 40% of salmon calcitonin when complexed into a NPs system using chitosan and hyaluronic acid. For oral delivery systems, NPs remain in the system for up to 6h after intake. Our studies show after 6h up to 85% release was obtained. However, a prolonged release is desired. Additional of an outer surface coating is a technique which has been widely used by a number of researchers in order to improve the integrity of the NPs and to better control the release profile (Elgadir et al., 2015). A popular approach to yield coated chitosan NPs is by polyelectrolyte complexation, which exploits the interaction between positively charged chitosan and negatively charged polyelectrolytes such as alginate (Garrait, Beyssac and Subirade, 2014), dextran (Sarmento et al., 2006), hyaluronic acid (Mero et al., 2014) or zein (Luo, Teng and Wang, 2012). Further work on LKP encapsulation will involve the polyelectrolyte complexation of LKP to achieve the desired release.

![Figure 10](image)

**Figure 10** Cumulative release profile of LKP from NPs in (a) SGF and (b) SIF for 24h.
4. Conclusions

LKP loaded NPs were formulated successfully by applying the ionotropic gelation technique. The optimal NPs were found at a ratio 5.9:1 (CL113: TPP), using the design of experiment approach, which resulted in reproducibility of the desirable physico-chemical characteristics. Optimally LKP NPs were spheroidal particles of size ~200nm, as shown by SEM, and had enhanced colloidal stability compared to the unloaded particles. A 5.9:1 ratio provided high encapsulation efficiency of 65±3% with loading capacity of approximately 5±0.8 %. Stability analysis showed long term physico-chemical stability. ACE inhibitory studies presented no change in bioactivity of LKP over the different temperature conditions and after formulation indicating it is quite stable. In addition, no cytotoxicity was observed from both the LKP loaded and unloaded NPs. In vitro release studies indicated an initial burst within 1h, suggesting the presence of more loosely bound tripeptide in the nanoparticle complex, followed by peptide bounded within the nanoparticle which is released at a slower rate. Chitosan based delivery systems is a feasible for the formulation of bioactive peptide, physicochemical analysis and stability was efficient. The present results indicate that the addition of an enteric coating to is recommended in order to bypass the stomach acidic pH conditions, providing an efficient delivery system.

Acknowledgements

This project is funded by an Irish Department of Agriculture Food Institutional Research Measure (FIRM) grant ‘NUTRADEL’ grant number 11F042. Special thanks to Dr Anne Shanahan for the assistance in image analysis.

References


http://doi.org/10.1016/j.carbpol.2013.02.031


http://doi.org/10.2147/IJN.S26365


http://doi.org/10.1021/bm301207a


http://doi.org/10.2174/0929866521666140807114240


http://doi.org/10.3390/md14060110


**Supplementary Material**

**S1:** Fitted results of 3rd order polynomial regression against the PDI, ZP, AE % and particle size for LKP-loaded NPs

<table>
<thead>
<tr>
<th>Variable</th>
<th>Polynomial regression equation:</th>
<th>Coefficient of determination (R²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size (nm)</td>
<td>a + bRatio + cRatio² + dRatio³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a = -284.90  c = -64.68</td>
<td>R² = 85.6%</td>
</tr>
<tr>
<td></td>
<td>b = 293.40    d = 4.51</td>
<td></td>
</tr>
<tr>
<td>PDI</td>
<td>a = 2.31      c = 0.12</td>
<td>R² = 83.2%</td>
</tr>
<tr>
<td></td>
<td>b = -0.88     d = 0.01</td>
<td></td>
</tr>
<tr>
<td>ZP (mV)</td>
<td>a = -16.80    c = -6.36</td>
<td>R² = 76.1%</td>
</tr>
<tr>
<td></td>
<td>b = 31.05     d = 0.42</td>
<td></td>
</tr>
<tr>
<td>AE (%)</td>
<td>a = 335.60    c = 43.79</td>
<td>R² = 50.2%</td>
</tr>
<tr>
<td></td>
<td>b = -202.40   d = -2.90</td>
<td></td>
</tr>
</tbody>
</table>

**S2:** Loading capacities of LKP-loaded NPs, n=3

<table>
<thead>
<tr>
<th>Sample</th>
<th>CL113 (mg/ml)</th>
<th>TPP (mg/ml)</th>
<th>Ratio (CL113/TPP)</th>
<th>LC %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.64</td>
<td>0.21</td>
<td>8.0</td>
<td>2.2±0.01</td>
</tr>
<tr>
<td>2</td>
<td>1.52</td>
<td>0.33</td>
<td>4.5</td>
<td>3.3±0.00</td>
</tr>
<tr>
<td>3</td>
<td>1.58</td>
<td>0.27</td>
<td>5.9</td>
<td>2.3±0.08</td>
</tr>
<tr>
<td>4</td>
<td>1.45</td>
<td>0.40</td>
<td>3.6</td>
<td>2.7±0.03</td>
</tr>
<tr>
<td>5</td>
<td>1.39</td>
<td>0.46</td>
<td>3.0</td>
<td>2.8±0.02</td>
</tr>
</tbody>
</table>